VWM
ZVRA icon

Venturi Wealth Management’s Zevra Therapeutics ZVRA Stock Holding History

Venturi Wealth Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-531
Closed -$4.43K – 1887
2024
Q4 		$4.43K Buy
+531
New +$4.53K ﹤0.01% 1720

Other funds holding ZVRA

Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Venturi Wealth Management's ZVRA Position: Q1 2025 in Review

Venturi Wealth Management sold out of Zevra Therapeutics (ZVRA) in Q1 2025, closing a stake of 531 shares — an estimated $4.43K sold.

Venturi Wealth Management first reported a position in ZVRA in Q4 2024 and held it in 1 quarter. The position peaked at $4.43K in Q4 2024. 110 funds tracked by Wall St. Rank hold ZVRA as of Q1 2025.

  • Venturi Wealth Management reported no remaining Zevra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 531 Zevra Therapeutics shares in Q1 2025, an estimated $4.43K.
  • Venturi Wealth Management first reported a position in Zevra Therapeutics in Q4 2024 and held it in 1 quarter.
  • Venturi Wealth Management's Zevra Therapeutics position peaked at $4.43K in Q4 2024.
  • 110 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.